Last updated: February 17, 2026
Overview of the Drug
NDC 69292-0566 is a prescription medication marketed under the trade name Retseptor. It is indicated for the treatment of chronic neuropathic pain in adults. The drug belongs to the class of selective serotonin-norepinephrine reuptake inhibitors (SNRI) with a mechanism targeting nerve pain modulation.
Market Size and Dynamics
Current Market Landscape
The chronic neuropathic pain market grew from approximately $4.2 billion in 2018 to $5.8 billion in 2022 globally, with an expected compound annual growth rate (CAGR) of around 7%. This growth stems from increasing prevalence of diabetes, cancer survivorship-related nerve pain, and greater recognition of neuropathic pain management.
Key Competitors
Major players include:
- Pregabalin (Lyrica): Proven efficacy, flexible dosing, first-mover advantage.
- Duloxetine (Cymbalta): Approved for diabetic neuropathy and fibromyalgia.
- Gabapentin (Neurontin): Widely prescribed, generic availability.
These drugs dominate due to established safety profiles and familiarity among prescribers.
Market Entry Factors for NDC 69292-0566
- Regulatory Approval: Achieved FDA approval in Q2 2022 based on phase 3 trial data demonstrating non-inferiority to Pregabalin.
- Pricing Strategy: Launched at an average wholesale price (AWP) of $250 per month, with discounts and rebates affecting net price.
- Distribution Channels: Available through major pharmacies, specialty clinics, and hospital formularies.
Price Trajectory Projections
Short-Term (Years 1-2)
- Initial Market Penetration: 1-3% of the neuropathic pain market due to limited prescriber familiarity.
- Average Monthly Price: $250–$270, considering rebates.
- Sales Volume: Approximate initial sales of 50,000 prescriptions in Year 1, increasing to 120,000 by Year 2 as prescriber acceptance grows.
Medium-Term (Years 3-5)
- Market Share Growth: 5–10%, reaching several hundred thousand prescriptions annually.
- Price Adjustment Trends: Slight decrease to $230–$250 due to generic competition, if generic versions enter the market.
- Annual Sales: Projected revenues around $180 million to $450 million, assuming steady uptake.
Long-Term (Years 6+)
- Market Maturity: Stabilizes with approximately 12% market share.
- Pricing: Competitive pressures could lower the monthly price to $200–$230.
- Market Penetration: 1.5–2 million prescriptions annually, depending on claims access and formulary placements.
Risk Factors Impacting Price and Market Share
- Patent Life and Exclusivity: The drug’s composition of matter patent expires in 2028, with 5-year data exclusivity ending in 2027, opening potential for generics.
- Generic Competition: Entry predicted within 2–3 years post patent expiry, likely causing a 30–50% price decline.
- Off-label Use and Prescriber Preference: Acceptance driven by clinical trial results and insurance coverage.
- Pricing Regulations: Increasing governmental pressure to reduce drug prices could impact the net revenue.
Policy and Reimbursement Environment
Medicare and private insurers prefer formulary inclusion based on cost-effectiveness. The drug’s inclusion depends on comparative effectiveness, especially in the context of generic options, which remain low-cost choices.
Conclusion
NDC 69292-0566's market potential is moderate initially, with growth contingent on prescriber acceptance and competitive pricing strategies. Long-term, the market will likely consolidate around generics, compressing margins but expanding volume.
Key Takeaways
- The drug entered a competitive neuropathic pain market with established players.
- Initial pricing targets approx. $250/month; sales are projected to grow steadily over five years.
- Patents and exclusivity protect revenue till 2028; generic competition expected from 2028 onwards.
- Price declines post-generic entry could reduce revenue by up to 50%, but increased volume can partially offset this.
FAQs
1. How does the patent timeline influence the drug's market value?
Patent expiry in 2028 allows generic manufacturers to produce lower-cost versions, significantly impacting pricing and market share.
2. What factors drive prescriber adoption of NDC 69292-0566?
Efficacy data, safety profile, insurance coverage, and formulary placement are primary drivers.
3. How might reimbursement policies affect profitability?
Stringent cost-containment and formulary restrictions can limit access and reduce revenue.
4. What is the significance of entry by generic competitors?
Generics typically lower overall market prices by 30–50% within 1–3 years of patent expiration.
5. How does the growth potential compare to current market leaders?
While initial uptake may be slower, long-term growth depends on differentiating features, clinical preference, and pricing strategies versus established alternatives.
References
[1] IQVIA, "Global Neuropathic Pain Market Data," 2022.
[2] FDA, "Drug Approval Packages," 2022.
[3] EvaluatePharma, "Pharmaceutical Market Forecasts," 2022.
[4] Centers for Medicare & Medicaid Services, "Drug Pricing and Reimbursement Policies," 2023.
